Fluticasone propionate/formoterol for COPD management: a randomized controlled trial
A Papi, D Dokic, W Tzimas, I Mészáros… - … journal of chronic …, 2017 - Taylor & Francis
Purpose To evaluate fluticasone propionate/formoterol (FP/FORM) in COPD. Patients and
methods COPD patients with forced expiratory volume in 1 s (FEV1)≤ 50% predicted and≥ …
methods COPD patients with forced expiratory volume in 1 s (FEV1)≤ 50% predicted and≥ …
Fluticasone propionate/formoterol for COPD management: a randomized controlled trial
A Papi, D Dokic, W Tzimas, I Meszaros… - International Journal of …, 2017 - go.gale.com
Purpose: To evaluate fluticasone propionate/formoterol (FP/FORM) in COPD. Patients and
methods: COPD patients with forced expiratory volume in 1 s ([FEV. sub. 1])[less than or …
methods: COPD patients with forced expiratory volume in 1 s ([FEV. sub. 1])[less than or …
Fluticasone propionate/formoterol for COPD management: a randomized controlled trial.
A Papi, D Dokic, W Tzimas, I Mészáros… - … Journal of Chronic …, 2017 - europepmc.org
Results In total, 1,765 patients were randomized. There were fewer discontinuations with
FP/FORM 500/20 µg (20.6%) and 250/10 µg (24.0%) compared with FORM (26.1%). None …
FP/FORM 500/20 µg (20.6%) and 250/10 µg (24.0%) compared with FORM (26.1%). None …
Fluticasone propionate/formoterol for COPD management: a randomized controlled trial
A Papi, D Dokic, W Tzimas, I Mészáros, A Olech-Cudzik… - 2017 - pubmed.ncbi.nlm.nih.gov
Purpose To evaluate fluticasone propionate/formoterol (FP/FORM) in COPD. Patients and
methods COPD patients with forced expiratory volume in 1 s (FEV 1)≤ 50% predicted and≥ …
methods COPD patients with forced expiratory volume in 1 s (FEV 1)≤ 50% predicted and≥ …
Fluticasone propionate/formoterol for COPD management: a randomized controlled trial
A Papi, D Dokic, W Tzimas, I Mészáros… - … Journal of Chronic …, 2017 - dovepress.com
Results: In total, 1,765 patients were randomized. There were fewer discontinuations with
FP/FORM 500/20 µg (20.6%) and 250/10 µg (24.0%) compared with FORM (26.1%). None …
FP/FORM 500/20 µg (20.6%) and 250/10 µg (24.0%) compared with FORM (26.1%). None …
Fluticasone propionate/formoterol for COPD management: A randomized controlled trial
A Papi, D Dokic, W Tzimas, A Olech-Cudzik… - INTERNATIONAL …, 2017 - sfera.unife.it
Purpose: To evaluate fluticasone propionate/formoterol (FP/FORM) in COPD. Patients and
methods: COPD patients with forced expiratory volume in 1 s (FEV1) ⤠50% predicted and …
methods: COPD patients with forced expiratory volume in 1 s (FEV1) ⤠50% predicted and …
[PDF][PDF] Fluticasone propionate/formoterol for COPD management: a randomized controlled trial
D Dokic, W Tzimas, I Mészáros… - … Journal of COPD, 2017 - scienceopen.com
Purpose: To evaluate fluticasone propionate/formoterol (FP/FORM) in COPD. Patients and
methods: COPD patients with forced expiratory volume in 1 s (FEV1)# 50% predicted and $1 …
methods: COPD patients with forced expiratory volume in 1 s (FEV1)# 50% predicted and $1 …
[PDF][PDF] Fluticasone propionate/formoterol for COPD management: a randomized controlled trial
D Dokic, W Tzimas, I Mészáros… - … Journal of COPD, 2017 - pdfs.semanticscholar.org
Purpose: To evaluate fluticasone propionate/formoterol (FP/FORM) in COPD. Patients and
methods: COPD patients with forced expiratory volume in 1 s (FEV1)# 50% predicted and $1 …
methods: COPD patients with forced expiratory volume in 1 s (FEV1)# 50% predicted and $1 …
[HTML][HTML] Fluticasone propionate/formoterol for COPD management: a randomized controlled trial
A Papi, D Dokic, W Tzimas, I Mészáros… - … Journal of Chronic …, 2017 - ncbi.nlm.nih.gov
Results In total, 1,765 patients were randomized. There were fewer discontinuations with
FP/FORM 500/20 µg (20.6%) and 250/10 µg (24.0%) compared with FORM (26.1%). None …
FP/FORM 500/20 µg (20.6%) and 250/10 µg (24.0%) compared with FORM (26.1%). None …
[PDF][PDF] Fluticasone propionate/formoterol for COPD management: a randomized controlled trial
D Dokic, W Tzimas, I Mészáros, Z Koroknai… - International Journal of …, 2017 - academia.edu
Purpose: To evaluate fluticasone propionate/formoterol (FP/FORM) in COPD. Patients and
methods: COPD patients with forced expiratory volume in 1 s (FEV1)# 50% predicted and $1 …
methods: COPD patients with forced expiratory volume in 1 s (FEV1)# 50% predicted and $1 …